Kimberly E. Vanover, SVP, Clinical Development at Intra-Cellular Therapies, Inc. (ITCI), sold 772 shares at $17.46 ($13K) on 2018-01-08, disclosed to the SEC on 2018-01-10.
Scheduled sale ($13k) by SVP, Clinical Development under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| ITCI | SELL | 2018-01-05 | $21K | — | Filing → |
| ITCI | SELL | 2017-01-09 | $13K | — | Filing → |
| ITCI | SELL | 2016-12-19 | $143K | — | Filing → |